Who
Geoffrey M. Parker
Director
Company insider
Files Form 4 as: Director, Perrigo Company; Chief Financial Officer, Allogene Therapeutics; Director, Better Therapeutics; Director, ChemoCentryx; COO, CFO and EVP, Tricida; Director, Genomic Health; Director, Sunesis Pharmaceuticals; Executive Vice President & CFO, Anacor Pharmaceuticals.
In numbers
- Trades disclosed
- 265
- Buys
- 57
- Sells
- 8
- Bought
- $9.1M
- Sold
- $3.3M
- Companies
- 9
- Companies where not an officer
- 6
- First trade
- 1 Jun 2010
- Last trade
- 11 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 15 Sep 2026 | PRGO Perrigo CompanyBiotechnology | SEC FORM 4 Code M | $17K1,263 at $13.66 | filing |
| 11 Sep 2026filed 15 Sep 2026 | PRGO Perrigo CompanyBiotechnology | SEC FORM 4 Code F | $8,292607 at $13.66 | filing |
| 11 Sep 2026filed 15 Sep 2026 | PRGO Perrigo Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,263 | filing |
| 11 Sep 2026filed 15 Sep 2026 | PRGO Perrigo Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,263 | filing |
| 11 Sep 2026filed 15 Sep 2026 | PRGO Perrigo CompanyBiotechnology | SEC FORM 4 Code M | $17K1,263 at $13.66 | filing |
| 11 Sep 2026filed 15 Sep 2026 | PRGO Perrigo CompanyBiotechnology | SEC FORM 4 Code F | $8,292607 at $13.66 | filing |
| 12 Jun 2026filed 16 Jun 2026 | PRGO Perrigo CompanyBiotechnology | SEC FORM 4 Code M | $11K976 at $10.99 | filing |
| 12 Jun 2026filed 16 Jun 2026 | PRGO Perrigo CompanyBiotechnology | SEC FORM 4 Code F | $5,154469 at $10.99 | filing |
| 12 Jun 2026filed 16 Jun 2026 | PRGO Perrigo Companyoption or derivative · Biotechnology | SEC FORM 4 Code A | —844 | filing |
| 12 Jun 2026filed 16 Jun 2026 | PRGO Perrigo Companyoption or derivative · Biotechnology | SEC FORM 4 Code A | —844 | filing |
| 12 Jun 2026filed 16 Jun 2026 | PRGO Perrigo Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —976 | filing |
| 12 Jun 2026filed 16 Jun 2026 | PRGO Perrigo Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —976 | filing |
| 12 Jun 2026filed 16 Jun 2026 | PRGO Perrigo CompanyBiotechnology | SEC FORM 4 Code M | $11K976 at $10.99 | filing |
| 12 Jun 2026filed 16 Jun 2026 | PRGO Perrigo CompanyBiotechnology | SEC FORM 4 Code F | $5,154469 at $10.99 | filing |
| 14 May 2026filed 15 May 2026 | PRGO Perrigo CompanyBiotechnology | SEC FORM 4 Code M | $79K7,305 at $10.84 | filing |
| 14 May 2026filed 15 May 2026 | PRGO Perrigo CompanyBiotechnology | SEC FORM 4 Code F | $38K3,507 at $10.84 | filing |
| 14 May 2026filed 15 May 2026 | PRGO Perrigo Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,305 | filing |
| 14 May 2026filed 15 May 2026 | PRGO Perrigo Companyoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,305 | filing |
| 14 May 2026filed 15 May 2026 | PRGO Perrigo CompanyBiotechnology | SEC FORM 4 Code M | $79K7,305 at $10.84 | filing |
| 14 May 2026filed 15 May 2026 | PRGO Perrigo CompanyBiotechnology | SEC FORM 4 Code F | $38K3,507 at $10.84 | filing |
News
Comparing eXoZymes (NASDAQ:EXOZ) and Allogene Therapeutics (NASDAQ:ALLO)ALLO · dailypolitical.com · 16 Oct 2026Contrasting Neurocrine Biosciences (NASDAQ:NBIX) and Perrigo (NYSE:PRGO)PRGO · dailypolitical.com · 10 Oct 2026Head to Head Comparison: Generate Biomedicines (NASDAQ:GENB) vs. Allogene Therapeutics (NASDAQ:ALLO)ALLO · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name Geoffrey M. Parker; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.